Physician profile
Sandra Benelli
NPI 1336681295
$2,802.23
in general payments reported to CMS, 2019-2025
33 companies · $870 in 2025
The $870 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $507 · 2023: $548 · 2024: $877 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $562.09 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $381.15 | 2022-2025 | Farxiga, Lokelma, Wainua |
| Novo Nordisk INC | $342.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $138.94 | 2022-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $123.94 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $109.16 | 2023-2025 | Verquvo |
| Abbott Laboratories | $88.56 | 2022-2023 | Gallant, Jot Dx, Jeti Peripheral Catheter |
| Baxter Healthcare | $84.92 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Novartis Pharmaceuticals Corporation | $72.85 | 2023-2025 | |
| Scpharmaceuticals INC. | $68.86 | 2025 | |
| Biotronik INC. | $63.06 | 2022-2024 | Biomonitor |
| Janssen Pharmaceuticals, INC | $57.17 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $57.11 | 2022-2025 | Opsumit |
| Kestra Medical Technology Services, INC. | $56.65 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $53.99 | 2025 | Attruby |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $53.28 | 2022-2025 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $50.06 | 2024 | Arcalyst |
| Atricure, INC. | $45.29 | 2023 | |
| Irhythm Technologies, INC. | $44.98 | 2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $42.65 | 2025 | Eliquis, Camzyos |
| Medtronic, INC. | $35.95 | 2025 | Micra |
| Angiodynamics, INC. | $33.33 | 2023 | Auryon Laser System 100-120 Vac |
| Vital Connect, INC | $29.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.20 | 2025 | Jardiance |
| Endotronix, INC. | $23.34 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Alnylam Pharmaceuticals INC. | $21.87 | 2025 | Amvuttra |
| Tactile Systems Technology INC | $20.54 | 2025 | Flexitouch Plus, Nimbl |
| Kiniksa Pharmaceuticals, LTD. | $20.50 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $20.00 | 2022 | |
| Boston Scientific Corporation | $20.00 | 2022 | |
| Philips North America LLC | $18.56 | 2025 | Diagnostic Ecg Service |
| Sanofi-Aventis U.S. LLC | $18.42 | 2023 | |
| Lilly USA, LLC | $13.51 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Benelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.